Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: a community-based randomized clinical trial in Guanacaste, Costa Rica.

Cancer Discovery
Rolando HerreroCosta Rica Vaccine Trial Group

Abstract

Target groups for human papillomavirus (HPV) vaccination are controversial. We evaluated vaccine efficacy (VE) against 1-year persistent infection, stratified by age and sexual behavior, among young women in Costa Rica. We randomized 7,466 healthy women 18 to 25 years of age to HPV16/18 or hepatitis A vaccine (follow-up, 50.4 months). According-to-protocol (ATP) cohorts included compliant HPV-negative women; intention-to-treat (ITT) included all randomized women. ATP VE was 90.9% (95% CI, 82.0-95.9) against HPV16/18 infections, 44.5% against HPV31/33/45 (95% CI, 17.5-63.1), and 12.4% (95% CI, -3.2 to 25.6) against any oncogenic infection. Overall ITT VE against HPV16/18 infections was 49.0%, but ATP and ITT VE almost reached 100% in year 4 of follow-up. ATP efficacy against HPV16/18 was similar by age, but ITT VE was greatest among youngest women (68.9% among those 18-19 years of age; 21.8% among those 24-25 years of age) and 79.8% among virgins. Among previously unexposed women, vaccination is highly efficacious against HPV16/18 and partially against HPV31/33/45. Vaccination is most effective in women and girls before they initiate sexual activity, with programmatic and individual decision implications.

References

Apr 23, 2002·JAMA : the Journal of the American Medical Association·Diane SolomonUNKNOWN Bethesda 2001 Workshop
Nov 22, 2002·The New England Journal of Medicine·Laura A KoutskyUNKNOWN Proof of Principle Study Investigators
Aug 21, 2007·JAMA : the Journal of the American Medical Association·Allan HildesheimUNKNOWN Costa Rican HPV Vaccine Trial Group
Sep 22, 2007·International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists·Joseph D CarreonMark Schiffman
Mar 28, 2008·Journal of the National Cancer Institute·Ana Cecilia RodríguezUNKNOWN Proyecto Epidemiológico Guanacaste Group
Aug 22, 2008·Journal of Clinical Microbiology·Philip E CastleUNKNOWN CVT Group
Feb 25, 2009·The Journal of Infectious Diseases·Rolando Herrero
Jun 12, 2009·Vaccine·Yuli ChangJennifer S Smith
Jul 30, 2009·BMJ : British Medical Journal·Philip E CastleUNKNOWN Proyecto Epidemiológico Guanacaste (PEG) Group
Feb 9, 2010·Journal of the National Cancer Institute·Nubia MuñozRichard M Haupt
Oct 15, 2010·Journal of the National Cancer Institute·Mahboobeh SafaeianUNKNOWN Costa Rican Vaccine Trial Group
Oct 19, 2010·The Lancet Oncology·Silvia de SanjoseUNKNOWN Retrospective International Survey and HPV Time Trends Study Group
Mar 16, 2011·The Journal of Infectious Diseases·Anil K ChaturvediUNKNOWN CVT Group
Apr 8, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M ArbynJ Ferlay

❮ Previous
Next ❯

Citations

Dec 20, 2013·Lancet·Paolo Vineis, Christopher P Wild
Jun 6, 2013·Nature Reviews. Clinical Oncology·Matti Lehtinen, Joakim Dillner
Dec 18, 2013·The New England Journal of Medicine·Mark Schiffman, Diane Solomon
Sep 13, 2011·Journal of the National Cancer Institute·Aimée R KreimerUNKNOWN CVT Vaccine Group
Mar 29, 2013·Journal of Virology·Subhashini JaguRichard B S Roden
Jun 14, 2013·Infectious Agents and Cancer·David HawkesMatthew J Berryman
Aug 21, 2014·American Journal of Epidemiology·Krystle A Lang KuhsUNKNOWN Costa Rica Vaccine Trial Group
Nov 28, 2013·Enfermedades infecciosas y microbiología clínica·Sonia Pérez-CastroSantiago Melón-García
Jun 25, 2014·The Journal of Infectious Diseases·Krystle A Lang KuhsUNKNOWN Costa Rica Vaccine Trial Group
Jul 12, 2013·American Journal of Epidemiology·Ana Cecilia RodríguezUNKNOWN CVT Group
Sep 6, 2014·Scandinavian Journal of Infectious Diseases·Matilde Trigo-DaportaUNKNOWN Pontevedra VPH-AR prevalence working group
Feb 21, 2016·Cancer Epidemiology·Marc ArbynSteven Weyers
Dec 5, 2012·Vaccine·John T SchillerSuzanne M Garland
Oct 3, 2015·Epidemiology and Infection·P E Castle, M Maza
Nov 22, 2015·Cancer Epidemiology·Patricia VillainRolando Herrero
Nov 1, 2015·The Journal of Infectious Diseases·Ariana HarariUNKNOWN Costa Rica HPV Vaccine Trial Group
Apr 30, 2016·International Journal of Applied & Basic Medical Research·Anshuma BansalBhavana Rai
Oct 16, 2015·Journal of the National Cancer Institute·Daniel C BeachlerUNKNOWN Costa Rica HPV Vaccine Trial (CVT) Group
Jun 14, 2015·The Lancet Oncology·Aimée R KreimerUNKNOWN GSK Vaccines Clinical Study Support Group
May 7, 2015·The Lancet Oncology·Rolando HerreroLauri E Markowitz
May 7, 2015·The Lancet Oncology·Douglas R LowyUNKNOWN Participants in the IARC/NCI workshop on Primary Endpoints for Prophylactic HPV Vaccine Trials
Feb 11, 2015·Human Vaccines & Immunotherapeutics·Alex VorstersPierre Van Damme
Dec 9, 2014·Human Vaccines & Immunotherapeutics·Hilary A RobbinsMahboobeh Safaeian
Mar 13, 2014·Vaccine·Carine DochezHelen Rees
Sep 6, 2014·Lancet·Philip E Castle, Kathleen M Schmeler
Mar 19, 2016·International Journal of Cancer. Journal International Du Cancer·Silvia FranceschiGary M Clifford
May 20, 2016·International Journal of Molecular Sciences·Alex VorstersPierre Van Damme
Apr 8, 2017·International Journal of Gynaecology and Obstetrics : the Official Organ of the International Federation of Gynaecology and Obstetrics·Giorgio BoganiFrancesco Raspagliesi
Jun 8, 2017·Diagnostic Cytopathology·Julieta E BarroetaCarolyn E Grotkowski
Oct 11, 2017·Viruses·Samuel AlizonIgnacio G Bravo

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

© 2021 Meta ULC. All rights reserved